Abstract
Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
Highlights
To the Editor: Improvements in managing b-thalassaemia major have allowed many patients to survive beyond puberty
Clinical data are limited regarding the use of chelation therapy during pregnancy, and it is unclear whether these agents pose any risk to the developing foetus
This case study discusses a patient who became pregnant while receiving deferasirox (ExjadeÒ; Novartis Pharmaceuticals Corp), the oncedaily, oral iron chelator
Summary
To the Editor: Improvements in managing b-thalassaemia major have allowed many patients to survive beyond puberty. Patients may require additional blood transfusions to treat complications such as pre-eclampsia or severe anaemia, increasing the need for effective iron chelation therapy. Clinical data are limited regarding the use of chelation therapy during pregnancy, and it is unclear whether these agents pose any risk to the developing foetus. There are case reports of successful pregnancies following treatment with deferoxamine (DesferalÒ; Novartis Pharmaceuticals Corp, East Hanover, NJ, USA) (10, 11).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
